The Month-6 Re-Review That Kills Peptide Accounts

The merchant account termination most peptide sellers never see coming does not happen at the initial underwriting stage. It happens at the six-month re-review, when acquirers run a scheduled re-underwriting check and compare what your business looks like today against the risk tolerance they hold today, not the one they held when they approved you. From what I have seen working with research compound businesses that process $25,000 or more per month, the six-month checkpoint is where the majority of post-approval account terminations in this vertical originate. Merchants who cleared initial underwriting without incident get offboarded because a catalog has grown without filed amendments, because product page language has drifted toward therapeutic claims, or because a chargeback ratio that was 0.4% at approval has climbed to 1.1% as a subscription cohort ages.

I am Jonathan Albert, Co-Founder of SeamlessChex. We help established businesses in high-risk verticals, including peptide and research compound sellers, find and keep stable credit card processing. This article covers the re-underwriting mechanism that terminates peptide accounts at month six: what acquirers are actually checking, which catalog and claim changes trigger the review, how chargeback trends function as the mathematical termination threshold, and the preparation steps that let a merchant arrive at re-review in a position to pass it. It is the piece of payment processing guidance that is almost entirely absent from the peptide space, and in my experience, it is the most practically important one for any seller currently running a live account.

What Is the Month-6 Re-Review and Why Does It Exist?

High-risk merchant accounts do not come with permanent approval. When an acquirer onboards a peptide business, it is underwriting a snapshot: the catalog as it existed on the application date, the chargeback history you reported, and the regulatory classification your products carried at that moment. What the acquirer does not commit to is underwriting your business indefinitely, regardless of how it changes.

Most peptide merchants do not know this. They clear initial approval, set up their payment gateway, and go to work building volume. Then, somewhere around month five or six, a letter arrives, or a webhook fires, or the gateway simply stops processing. The account has been suspended pending re-review, or terminated outright.

From what I have seen working with peptide and research compound sellers, the six-month mark is the most common trip wire. This is not a coincidence. Acquirers and their sponsor banks build periodic re-underwriting cycles into high-risk agreements specifically because the regulatory and product landscape in this vertical moves quickly. A compound that was legally positioned as "research use only" when you applied may have moved into a disputed classification by the time the review runs. Your chargeback ratio, which was 0.3% at approval, may have climbed to 1.1% by month six as your subscription cohort ages. Your product page language, which was clean at onboarding, may have quietly drifted toward therapeutic claims as your marketing team optimized copy for conversions.

Acquirers use the re-review to catch all of this. Here is what the checklist typically covers:

• Catalog audit: Are the products being processed the same products that were approved?
• Claims audit: Do current product descriptions, landing pages, and social media match the language from the original application?
• Chargeback ratio: Has the rolling three-month dispute ratio crossed 1% for Visa or 1.5% for Mastercard?
• Regulatory status: Has the regulatory classification of any SKU changed since approval, for example due to FDA enforcement actions or new compounding rules?
• Processing volume vs. projected: Is actual monthly volume within the range disclosed at underwriting?

The key detail most merchants miss: you are re-underwritten against the risk tolerance your acquirer holds today, not the tolerance they held when they approved you. If a sponsor bank has tightened its policy on research compounds in the intervening months because of regulatory pressure or chargeback trends across its portfolio, your account may not survive re-review even if you have done nothing wrong. I have seen exactly this happen to merchants with clean ratios and compliant catalogs.

This is not a technicality. It is the structural reality of high-risk payment processing. Understanding it is the first step toward surviving it.

What Acquirers Are Actually Checking at the Six-Month Mark

When a re-underwriting review opens on a peptide account, two analysts are typically working it: one on the risk side, one on the compliance side.

The risk analyst is looking at transaction data. The compliance analyst is looking at your storefront. Both sets of findings go into the same decision packet.

In my experience working with high-risk merchants, the compliance side of the review is what most sellers underestimate. They prepare their financials, monitor their chargebacks, and assume that keeping dispute rates low is the whole game. It is not. The compliance analyst is visiting your website, your product pages, your checkout flow, and often your social media channels. They are comparing what they see against what you submitted on your original application.

Here is where many peptide accounts fail this audit:

• Therapeutic language on product pages: Phrases like "supports healing," "reduces inflammation," or "promotes recovery" can read as implied health claims. At initial underwriting, many sellers scrub their pages. By month six, marketing copy has often crept back toward benefit language as A/B testing reveals what converts.
• New SKUs not disclosed to the processor: Adding a new peptide product mid-agreement without notifying the acquirer is a common termination trigger. The acquirer approved a specific catalog. Adding new compound variants or combination stacks without filing a catalog amendment is a material change that voids the original underwriting.
• Subscription billing model changes: If you converted from one-time purchases to a subscription-default model after approval, the risk profile of your account changed. Acquirers care because subscriptions create future chargeback exposure from cardholders who later forget they enrolled.
• Social media and influencer content: Acquirers and their sponsor banks increasingly review external-facing content linked or attributed to the merchant. A video by a brand ambassador claiming a peptide "healed" something is a compliance flag that can surface in a re-review.

On the risk side, the analyst is focused on three numbers above everything else: the chargeback ratio, the refund rate, and the fraud-to-volume ratio. Visa's chargeback monitoring program threshold is 1%. Mastercard's is 1.5%. Peptide merchants running subscription models are particularly vulnerable to breaching these thresholds at month six because the first cohort of subscribers is now old enough to have forgotten they enrolled, disputed charges, or experienced delivery issues.

There is a third element that matters and that almost no one accounts for: sponsor bank appetite shifts. Acquirers do not hold all their risk. They pass it upstream to sponsor banks, which are regulated institutions subject to OCC and Federal Reserve oversight. If the sponsor bank has issued new internal guidance on research compounds because of an enforcement letter, an industry investigation, or category-wide chargeback pressure, your acquirer must comply regardless of your individual account performance. Accounts with clean chargeback ratios and pristine compliance records can be terminated at re-review because the sponsor bank changed its category policy entirely.

Knowing which of these vectors is most likely to affect your account is the foundation of surviving the six-month review.

Which Catalog and Claim Changes Trigger Re-Underwriting

The peptide regulatory landscape has not stood still. In 2023 and 2024, the FDA changed guidance in ways that effectively closed the compounding pharmacy route for several non-approved peptides.

In mid-2026, the Pharmacy Compounding Advisory Committee held a formal vote on whether to permit compounding of BPC-157, TB-500, MOTS-c, and several other compounds under the 503A Bulks List framework, voting 8-6-1 on Day 1 to recommend their addition. Two peptides commonly found in the research market are banned by the World Anti-Doping Agency. The regulatory picture for this category changes faster than most merchant agreements are renegotiated.

This creates a specific hazard for peptide sellers: the product you launched with may carry a different regulatory classification at month six than it did on your application date. Acquirers track FDA enforcement letters, advisory committee decisions, and scheduling actions. If a compound in your catalog becomes the subject of an enforcement action between your approval date and your re-review date, that is a material change that can justify account termination, even if your own operations have been flawless.

Here are the catalog and claim changes that most often trigger re-underwriting in the peptide space:

The claims language issue is where I see the most merchants caught off guard. When a peptide merchant first applies, legal or compliance counsel typically reviews every word on the product pages. Six months later, the marketing team has been running conversion tests and has quietly moved toward language that performs better in paid traffic. Higher-converting language often bleeds toward benefit claims, and benefit claims on unapproved research compounds are exactly what compliance reviewers flag.

Specific phrases that surface in termination notices from acquirers in this space include "tissue repair," "anti-inflammatory effects in humans," "speeds recovery from injury," and "supports GH secretion." These are not speculative examples. They represent the kind of language that signals an approved research compound is being marketed for human therapeutic use, which is a different category than the one your account was underwritten to process.

The practical rule: If a claim could appear in a clinical trial abstract, it does not belong on your research compound product page. Keep product descriptions to molecular structure, purity, concentration, and research context. Let customers' own research drive the conversation from there.

Month-6 Re-Review Readiness Checklist

Use this checklist at month three to identify gaps before your acquirer does at month six.

PEPTIDE MERCHANT: PRE-REVIEW COMPLIANCE CHECKLIST
================================================
TARGET: Complete by Month 3 (90 days before re-review)
[ ] CATALOG INTEGRITY
- List every product currently in processing
- Compare against the catalog submitted at original underwriting
- File written catalog amendment with processor for any additions
- Confirm no new compound variants or combination stacks were added unreported
[ ] CLAIMS AUDIT
- Review all product page copy line by line
- Flag any phrasing that implies human therapeutic use:
“supports healing / tissue repair / recovery / GH secretion”
- Rewrite flagged copy to: molecular structure, purity, concentration, research context only
- Repeat audit for all landing pages, email flows, and social media bios
[ ] CHARGEBACK RATIO
- Pull rolling 90-day chargeback ratio (target: under 0.75%)
- If over 0.75%: implement pre-billing notifications + refund-first policy immediately
- Confirm account updater service is active for card-on-file subscriptions
[ ] DOCUMENTATION PACKAGE
- Current COAs for all products in processing (dated within 6 months)
- Current business license / state registration
- 3-month bank statements (most recent)
- Chargeback ratio trend report (3-month rolling)
- Reserve account balance confirmation
[ ] BILLING MODEL
- Confirm no billing model changes since original underwriting
- If subscription was added post-approval: file notification with processor
[ ] REGULATORY SCAN
- Review FDA enforcement letters issued in the past 6 months for any compound in catalog
- Check WADA prohibited list for any compound in catalog
- Document findings; update processor if any regulatory status has changed

How Chargeback Trends Seal a Peptide Account's Fate

Chargebacks are the most mechanical termination trigger in the peptide space, because the thresholds are quantitative and universally applied.

Visa considers a merchant "at risk" at a 1% chargeback-to-transaction ratio and places them in a formal monitoring program at that level. Mastercard's equivalent threshold is 1.5%. Breach either for two or more consecutive months and your acquirer's risk team will almost certainly be notified, and your account placed under review.

Peptide merchants are structurally exposed to chargeback risk in ways that generic e-commerce businesses are not. Three patterns account for most of the exposure:

Subscription billing and the forget-and-dispute cycle. The upside of subscription-default models for peptide brands is well documented. One operator in this space scaled a peptide brand from $7,000 in month-one ad spend to $600,000 in a single month, largely on the strength of recurring billing. The downside is that subscribers who forget they enrolled, receive credit card statements they do not recognize, or lose renewal notification emails are prime candidates for friendly fraud disputes. At month six, the first cohort of subscribers who signed up in month one are old enough to have cycled through one or two billing periods they did not anticipate. Dispute rates climb, often sharply.

Gray market supply chain and fulfillment problems. U.S. peptide imports from China roughly doubled in 2025, reaching approximately $328 million in just the first three quarters of the year, according to customs data reported by The New York Times. The supply chain for many research compounds runs through international channels with their own quality control and shipping reliability variables. Delayed shipments, damaged or mislabeled products, and purity inconsistencies create refund requests and chargebacks that have nothing to do with the merchant's billing practices but still count against their ratio.

Platform shutdowns and account migration spikes. When Stripe, a CRM platform, or another processor terminates a peptide seller, that seller's customers experience billing failures, fulfillment gaps, and confusion about their subscription status. The operational disruption of a platform shutdown creates a spike in disputes that follows the merchant to their next processor. If the spike lands inside a re-review window, it can terminate a new account before it has time to stabilize.

A practical chargeback prevention protocol for the months leading into a re-review should include:

• Weekly ratio monitoring, not monthly. By the time a monthly report shows you at 0.9%, you may already be at 1.2% in real time. Weekly visibility lets you intervene before you breach.
• Pre-billing subscriber notifications. Send a reminder 72 hours before any recurring charge. This single step measurably reduces friendly fraud disputes from customers who forgot they enrolled.
• Account updater services. Expired cards are a leading source of failed charges that push frustrated customers toward disputes. Automatic card-on-file updates prevent a significant share of those failures before they become problems.
• Meticulous fulfillment documentation. Shipping confirmation, tracking, and delivery records are the defense against "item not received" chargebacks. If it is not documented, it did not happen in a dispute adjudication.
• Refund-first policy. A refund costs you the sale. A chargeback costs you the sale, a fee, and a mark against your ratio. Offer the refund first when a customer is escalating toward a dispute.

The goal going into a re-review is to present chargeback data that shows a trend, not just a snapshot. An account that enters re-review at a 0.8% ratio but shows a three-month declining trend from 1.1% tells a different story than one that arrived at 0.8% from a flat baseline. Acquirers look at trajectory, not just the current number.

How to Prepare Your Peptide Business for the Re-Review Cycle

The merchants who survive the month-six re-review do not do it by accident. They do it because they treat re-underwriting as a scheduled business process, the same way they treat quarterly inventory planning or tax preparation. The review is coming. The only variable is whether you arrive at it prepared.

In my experience helping established peptide businesses find and maintain stable credit card processing, the merchants who come through re-reviews intact share a specific set of behaviors. They are not reactive. They have built the work of re-underwriting preparation into their operating calendar months before the review arrives.

They file catalog amendments proactively. Every time they add a new SKU, change a product formulation, or revise core product descriptions, they notify their processor in writing before the change goes live. This creates a documented record that positions the change as authorized rather than discovered during audit. It also gives the acquirer an opportunity to flag a potential compliance concern before it becomes a termination event.

They audit their own compliance language quarterly. They do not rely on their marketing team to self-police. They run a structured review of every product page, every landing page, and every active email sequence against the language that was present in their original underwriting submission. Any drift toward therapeutic claims gets corrected before a reviewer sees it. One useful test: read each product description and ask whether it could appear verbatim on a licensed drug manufacturer's product sheet. If the answer is yes, the language needs to change.

They maintain rolling documentation packages. The documentation package that got them approved at month zero is insufficient at month six. Going into any re-review, they should be able to produce current certificates of analysis for all products in processing, current business registration and licensing documents, a clean three-month bank statement showing stable cash flow, a chargeback ratio trend report, and a log of any remediation steps taken since the last review.

They keep their reserve accounts properly funded. Most high-risk merchant agreements include a rolling reserve, typically between 5% and 15% of monthly processing volume, held back against potential future chargebacks. Merchants who attempt to negotiate reserves down aggressively or dispute reserve holds going into a re-review create friction that signals financial instability to an underwriter. A properly funded reserve is not a cost; it is evidence of a financially healthy operation.

SeamlessChex works with established peptide and research compound businesses that process a minimum of $25,000 per month. That means we are working with merchants who have operational history, real transaction data, and the business maturity to structure agreements built for durability. The conversations I have most often with peptide merchants who come to us after a termination follow a consistent pattern: they did not know the re-review was coming, or they knew it was coming but did not understand what it evaluated.

Preparation is not complicated. It is systematic. A peptide business that runs quarterly internal compliance audits, files catalog changes proactively, and manages its chargeback ratio as a standing operational metric is a business that re-underwriting teams see as low-risk. Getting approved is the beginning. Staying approved is the work.

What Will Matter Most for Peptide Payment Processing in the Next 12-24 Months

The regulatory environment for peptide compounds is moving faster than at any point in the last decade. The FDA's Pharmacy Compounding Advisory Committee voted in mid-2026 to recommend adding BPC-157, TB-500, MOTS-c, and other compounds to the 503A Bulks List, which would formally permit their individual compounding pursuant to a physician's prescription. That decision, if it becomes final policy, does not make these compounds FDA-approved. It makes them more formally accessible through licensed compounding pharmacies, which is a different thing. For payment processors and their acquirers, it may shift how certain catalog presentations are evaluated during re-underwriting. But it does not eliminate re-review cycles.

From my perspective, three forces will most shape the peptide payment landscape over the next 12 to 24 months:

Sponsor bank consolidation around research compound policies. As acquirers accumulate portfolio-level data on peptide merchant chargeback trends, the sponsor banks behind them are developing more formalized internal policies on research compound categories. I expect to see the informal tolerance that existed for the first wave of peptide merchants replaced by more explicit, written category criteria, both for initial approval and for re-underwriting. This makes the documentation and compliance standards that currently separate successful merchants from terminated ones more important, not less.

Subscription billing scrutiny will intensify. The subscription model has proven itself commercially for peptide brands. It has also proven itself as a chargeback generator at scale. As processors accumulate data on how subscription-default peptide businesses perform through their six-month and twelve-month cycles, the scrutiny applied to subscription billing models during re-underwriting will become more granular. Merchants who can demonstrate controlled chargeback trends, documented subscriber management protocols, and proactive dispute resolution will be meaningfully better positioned than those who cannot.

Regulatory reclassification events will create category-wide account reviews. Every time the FDA takes a formal enforcement action against a specific peptide compound, acquirers across the industry re-evaluate their entire peptide portfolio exposure. The PCAC vote in July 2026 generated exactly this kind of review cycle across processors. Future regulatory decisions, in either direction, will do the same. A merchant who maintains real-time awareness of the regulatory status of every compound in their catalog, and who files proactive processor notifications when regulatory status changes, is the merchant who weathers these events without account interruption.

The merchants who will hold stable processing arrangements through this period are the ones who have already internalized that payment compliance is an operational function, not a one-time onboarding task.

How SeamlessChex Helps Peptide Merchants Stay Approved

SeamlessChex is a credit card processing and fintech payments platform that has been helping established businesses move money for more than 10 years. For peptide and research compound merchants, that means structuring merchant accounts designed to hold through re-underwriting cycles, not just clear initial approval. We work with businesses processing a minimum of $25,000 per month, which means the merchants we partner with have transaction history, operational maturity, and the business profile that makes durable processing agreements possible.

In practice, what that looks like is a hands-on onboarding process that sets catalog documentation, reserve terms, and compliance language expectations from day one. It means a processor who knows what the six-month re-review evaluates and can help you prepare for it proactively, not reactively. And it means a partner who understands both the compliance environment for research compounds and the payment infrastructure that keeps your billing running through it.

If your peptide business is approaching the six-month mark, has already been terminated and is evaluating new processing options, or is scaling toward volume that requires a more stable processing relationship, connect with our team to discuss what a merchant account built for this vertical looks like. We approve established merchants who are processing at scale and who want to stay that way.

Learn more about peptide payment processing with SeamlessChex or contact our team directly to discuss your account.